Discovery of GNE-6893, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of HPK1-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Discovery of GNE-6893, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of HPK1

Published:2024-09-03 Issue: Volume: Page:
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Tellis John C.¹^ORCID,Wei BinQing¹^ORCID,Siu Michael¹^ORCID,An Le¹,Chan Grace Kayan¹,Chen Yong²,Du Xiangnan¹,Gazzard Lewis¹^ORCID,Hu Baihua²,Kiefer James¹,Kakiuchi-Kiyota Satoko¹,Lainchbury Michael³,Linehan Jonathan L.¹,Luo Xifeng²,Malhotra Sushant¹,Mendonca Rohan¹,Pang Jodie¹,Ran Yinqing¹,Sethuraman Vijay¹,Seward Eileen³,Sneeringer Chris¹,Su Dian¹^ORCID,Wang Weiru¹,Wu Ping¹,Moffat John G.¹,Heffron Timothy P.¹,Choo Edna F.¹^ORCID,Chan Bryan K.¹

Affiliation:

1. Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States

2. Pharmaron Beijing Co., No. 6 Tai He Road, BDA, Beijing 100176, P.R. China

3. Charles River Laboratories, 8-9 Spire Green, Flex Meadow, Harlow, Essex CM19 5TR, United Kingdom

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.4c00319

Reference30 articles.

1. Oncology Meets Immunology: The Cancer-Immunity Cycle

2. Current Status and Future Directions of the Immune Checkpoint Inhibitors Ipilimumab, Pembrolizumab, and Nivolumab in Oncology

3. Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential

4. Combination cancer immunotherapy and new immunomodulatory targets

5. Small Molecules for Cancer Immunotherapy

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP